Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 0
Stock impact report

Adamas Gets Beat Down For Beating Q3 Estimates [Seeking Alpha]

Adamas Pharmaceuticals, Inc. (ADMS) 
Last adamas pharmaceuticals, inc. earnings: 2/25 04:03 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.adamaspharma.com/investors
Company Research Source: Seeking Alpha
Summary Source Company Overview Adamas Pharmaceuticals, Inc. ( ADMS ) is a commercial stage pharmaceutical company that specializes in developing chrono-synchronous therapies for chronic neurologic disorders. Figure 1 illustrates the Adamas portfolio that focuses around their principal drug GOCOVRI. Figure 1: ADAMSAS Portfolio (Source ADAMAS ) In August 2017, the FDA approved GOCOVRI for levodopa induced dyskinesia (LID) for Parkinson’s disease ( PD ) patients. GOCOVRI is the first and only approved drug for this indication. It is taken once daily at bedtime, and is offered in extended-release capsules in 68.5 mg and 137 mg strength. Adamas reformulated generic amantadine and used the FDA 505(2) (NYSE: B ) pathway to expedite the approval process. The GOCOVRI amantadine reformulation is an extended release formula. Whereas, the generic formula is an immediate release, and has been prescribed “off-label” for treating dyskinesia in Show less Read more
Impact Snapshot
Event Time:
ADMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for ADMS alerts
Opt-in for
ADMS alerts

from News Quantified
Opt-in for
ADMS alerts

from News Quantified